加拿大皇家银行(RBC)将MoonLake Immunotherapeutics的投资评级从"跑赢大盘"下调至"板块表现",同时大幅下调目标价,从此前的67美元降至10美元。
加拿大皇家银行(RBC)将MoonLake Immunotherapeutics的投资评级从"跑赢大盘"下调至"板块表现",同时大幅下调目标价,从此前的67美元降至10美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.